Amgen Revenue Exceeds Expectations; Threats Remain Despite New Launches
This article was originally published in Scrip
Amgen Inc. reported $5.7bn in third quarter revenue, exceeding analyst estimates by $400m and beating the year-ago period by 14%, but the growth was fueled by a combination of higher demand, product price increases and built-up inventories without significant contributions from new medicines.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.